Skip to main content

Dr. Thomas Carr is a registered patent attorney and represents domestic and international clients in intellectual property litigation and counseling. He specializes in the fields of molecular biology, pharmaceuticals, pharmaceutical small molecules, nutraceuticals, contraceptives, cell and gene therapies, regenerative medicine, immunotherapy, dermatological compositions, bioinformatics, diagnostics, and medical products and devices.

Thomas represents clients in all phases of patent litigation, from pre-suit diligence and the filing of a complaint through appeal. Thomas has significant deposition, court hearing, and trial experience. His litigation experience includes district court infringement actions, Federal Circuit appeals, ANDA litigation under the Hatch-Waxman Act, and Section 1498 litigation against the United States of America. He also develops patent portfolios for clients. He has significant experience preparing, prosecuting, and obtaining patents for clients, counseling clients on portfolio management, and rendering opinions on infringement, freedom-to-operate, and risks associated with ANDA filings.

While pursuing his Ph.D. at the University of Delaware, Thomas wrote his dissertation titled "Expanding the Avian Micro RNA Repertoire of Domesticated Poultry and Investigating the NLRP3 Inflammasome Messenger RNA and Micro RNA Transcriptomes in Anas Platyrhynchos (Ducks)." He focused his research on miRNA characterization, investigating the avian upper respiratory viral microbiome, and developing sequencing pipelines using open source software for DNA, RNA, and miRNA transcriptomes. His technical experience includes biochemistry, bioinformatics, computational biology, and virology.

Prior to graduate school, Thomas obtained his bachelor's degree in biochemistry at Widener University. While at Widener, Thomas wrote a senior thesis titled "Early Splicing Factors Influence Triglyceride Levels in Drosophila Melanogaster (Fruit Fly)." His research involved investigating factors contributing to disease phenotypes and developing quantitative assays.




  • J.D., Law/Intellectual Property, Antonin Scalia Law School at George Mason University, 2020
  • Ph.D., Molecular Biology & Genetics, University of Delaware, 2017
  • B.S., Biochemistry, Widener University, 2010


  • District of Columbia
  • U.S. Patent and Trademark Office